Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset
Source: SeekingAlpha
2025-12-09 10:53:32 ET
More on Vor Biopharma
- Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise
- Vor Biopharma slumps 26%, prices $100M equity at $10 per share
- Vor Bio launches $100M public stock offering
- Seeking Alpha’s Quant Rating on Vor Biopharma
- Historical earnings data for Vor Biopharma
Read the full article on Seeking Alpha
For further details see:
Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset
Remegen Co Ltd Reg Shs
NASDAQ: REGMF
REGMF Trading
0.0% G/L:
$10 Last:
1,500 Volume:
$10 Open:
